ADORA2A and Parkinson disease: It seems possible that early treatment with A2AR and/or mGluR5 antagonists can help stop this reorganization of the receptor panorama and counteract the wearing off of the antiparkinsonian effects of levodopa and D2R agonists and delay their introduction in the treatment of patients with Parkinson's disease.